Optimizing Community-Based Decisions: HER2-Positive Metastatic Breast Cancer

Optimizing Community-Based Decisions: HER2-Positive Metastatic Breast Cancer

Optimizing Community-Based Decisions: HER2-Positive Metastatic Breast Cancer
RestartResume

Put yourself to the test in this interactive simulation designed to elevate your knowledge and skills around emerging scientific data in HER2+ mBC.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    HER2 is overexpressed and/or amplified in about 20% of breast cancers. HER2 positivity signifies an aggressive tumor; however, it also opens the door for targeted therapeutic options. In advanced or metastatic disease, a patient’s prognosis has greatly improved with the emergence of new anti-HER2 therapies. With the addition of these newer treatment options, physicians have a multitude of therapies to choose from, but patient-specific characteristics and sequencing still present a challenge.

    In this interactive simulation, clinicians will be mentored through 2 different case-based examinations and will have the opportunity to make patient-specific treatment selections and manage treatment-related adverse events. Find out what changes you can make in your practice today to benefit your patients with HER2-positive metastatic breast cancer.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Sara A. Hurvitz, MD, FACP
    Professor of Medicine
    Director, Breast Cancer Clinical Trials Program, Division of Hematology-Oncology
    David Geffen School of Medicine, UCLA
    Santa Monica, CA

    Contracted Research: Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, MacroGenics, Novartis, Pfizer, OBI Pharma, Pieris, Puma, Radius, Samumed, Sanofi, Seattle Genetics, Dignitana, Zymeworks, Phoenix Molecular Designs, Ltd.
    Ownership Interest: NKMax; (spouse): ROMTech, Ideal Implant

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nicole Fox, DNP, MSN-Ed., RN, OCN, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify optimal therapy selection for specific subpopulations with HER2-positive MBC
    • Demonstrate optimal treatment planning based on individual patient characteristics in the HER2-positive MBC setting
  • Target Audience

    This activity is designed to meet the educational needs of community medical oncologists, academic medical oncologists, and pathologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative (GLC) designates this DecisionSim activity for a maximum 0.25 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 Nursing contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, and Seagen.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free